Firefly Neuroscience Files 8-K on Shareholder Votes & Exhibits
Ticker: AIFF · Form: 8-K · Filed: Feb 14, 2025 · CIK: 803578
Sentiment: neutral
Topics: corporate-governance, financial-reporting, filing-update
Related Tickers: WAVD
TL;DR
Firefly Neuroscience (WAVD) filed an 8-K for shareholder votes and financials.
AI Summary
Firefly Neuroscience, Inc. filed an 8-K on February 14, 2025, reporting on the submission of matters to a vote of security holders and financial statements and exhibits. The company, formerly known as WAVEDANCER, INC. and INFORMATION ANALYSIS INC, is incorporated in Delaware and has its principal executive offices in Kenmore, NY.
Why It Matters
This filing indicates important corporate actions and financial reporting, which are crucial for investors to understand the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine filing for corporate actions and financial reporting, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- FIREFLY NEUROSCIENCE, INC. (company) — Registrant
- WAVEDANCER, INC. (company) — Former company name
- INFORMATION ANALYSIS INC (company) — Former company name
- February 14, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Kenmore, NY (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item information, but the specific details of these matters are not provided in this excerpt.
What financial statements and exhibits are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item information, but the specific content of these documents is not detailed in this excerpt.
When was Firefly Neuroscience, Inc. previously known by other names?
The company was formerly known as WAVEDANCER, INC. (name change date 20211215) and INFORMATION ANALYSIS INC (name change date 19920703).
What is the principal executive office address of Firefly Neuroscience, Inc.?
The principal executive offices are located at 1100 Military Road, Kenmore, NY 14217.
What is the Commission File Number for Firefly Neuroscience, Inc.?
The Commission File Number is 001-41092.
Filing Stats: 679 words · 3 min read · ~2 pages · Grade level 13.6 · Accepted 2025-02-14 16:49:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share AIFF The Nasdaq Capital M
Filing Documents
- wavd20250214_8k.htm (8-K) — 31KB
- 0001437749-25-004033.txt ( ) — 160KB
- wavd-20250214.xsd (EX-101.SCH) — 3KB
- wavd-20250214_def.xml (EX-101.DEF) — 11KB
- wavd-20250214_lab.xml (EX-101.LAB) — 15KB
- wavd-20250214_pre.xml (EX-101.PRE) — 11KB
- wavd20250214_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On February 14, 2025, Firefly Neuroscience, Inc., a Delaware corporation (the "Company"), held a special meeting of stockholders (the "Special Meeting"). As of January 6, 2025, the record date for the Special Meeting, there were 7,945,480 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Special Meeting, of which 3,537,940 shares, or approximately 44.52%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of common stock are entitled to one vote for each share held. The proposals are described in greater detail in the Company's Definitive Proxy Statement on Schedule 14A , as filed with the Securities and Exchange Commission on January 21, 2025 (the "Proxy Statement"), the relevant portions of which are incorporated by reference herein. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Special Meeting. (i) A proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of 20% or more of our issued and outstanding common stock of the Company, pursuant to the Securities Purchase Agreement, dated as of December 20, 2024, between the Company and Helena Special Opportunities LLC ("Helena"), including upon the conversion of a convertible note issued to Helena and upon the exercise of a warrant issued to Helena. The proposal was approved as set forth below: For Against Abstain 3,521,591 13,620 2,729 (ii) A proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of 20% or more of our issued and outstanding common stock pursuant to the Purchase Agreement, dated December 20, 2024, between the Company and Arena Business Solutions Global SPC II, Ltd. The proposal was approved as set forth below: For Against Abstain 3,507,141 27,770 3,029
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 14, 2025 FIREFLY NEUROSCIENCE, INC. /s/ Greg Lipschitz Name: Greg Lipschitz Title: Interim Chief Executive Officer